One of the most challenging parts of cancer treatment is the hair loss, but thanks to one non-profit, it doesn't have to be.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.71, along ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Omaha nonprofit goes on its eighth year of packing and distributing care packages for breast cancer survivors.